As mentioned in Article 1, Round 10 applicants from countries that have concentrated HIV/AIDS epidemics within "most-at-risk populations" (MARPs) have the option of applying for funding specifically for MARPs under a new funding stream.
You are here
The Global Fund Board's delegation of Communities Living with HIV, TB and affected by malaria is looking for people willing to be part of the delegation for a three-year period, from 2011 through 2013.
The Global Fund today (21 May 2010) issued an unusual press release protesting the conviction and sentencing of two men in Malawi based on their sexual orientation.
The Global Fund is supporting programmes that address HIV-related human rights issues; however, countries do not appear to be using this opportunity to establish and scale up all of the programmes needed to reduce stigma and discrimination and increase access to justice in national responses to HIV.
The Global Fund Secretariat is working with 20 countries in sub-Saharan Africa to assess the possibility of reprogramming existing Global Fund grants to allow for a switch from the use of single dose nevirapine to more effective dual or triple ARV therapy for the prevention of mother-to-child transmission (PMTCT).
As of 31 March 2008, a recently completed Round 1 Global Fund grant in Ukraine had provided prevention services to 214,103 people who inject drugs. By the end of September 2008, 6,070 people, including 911 children, had received antiretroviral therapy (ART). And, in 2008, 80% of pregnant women living with HIV had received treatment to prevent mother-to-child transmission, up from 35% in 2003.
The Global Fund Board has approved two of the nine Round 9 proposals whose original rejection had been appealed by the applicants. The newly approved proposals are an HIV proposal from Pakistan that will cost $11.9 million and a TB proposal from Ukraine that will cost $34.6 million (costs are for the first two years). The approvals are subject to a number of requests for clarification being successfully responded to in a timely manner.
In December 2009, the Global Fund Board approved nine proposals in Wave 7 of the rolling continuation channel (RCC) funding stream, representing costs of up to $451 million over three years. Of the nine proposals, three were for HIV, four for TB and two for malaria. All approvals are conditional on the applicant responding satisfactorily to clarifications requested by the Technical Review Panel (TRP).
In Issue 111, GFO reported briefly on a Global Fund Board decision in November 2009 to further modify its Quality Assurance Policy for Pharmaceutical Products. This article provides some background information and further details of the decision.
The Board had previously approved a revised Quality Assurance Policy at its meeting in November 2008. That revised policy came into effect on 1 July 2009.
By 30 November 2009, programmes supported by the Global Fund were providing antiretroviral (ARV) treatment to 2.5 million people living with HIV, an increase of 25% compared to 2008. Global Fund-supported programmes were also providing directly observational therapy short course (DOTS) to 6.0 million people with TB, an increase of 30%; and had distributed 104 million insecticide-treated mosquito bed nets, an increase of 49%.